Skip to main content

Table 2 Summary of clinical efficacy outcomes by the Steering Committee

From: Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial

Patient number

Bleeding risk factors

Thrombotic risk factors

HIT

Baseline thrombosisa

New/extended thrombosis

Major bleeding

Bleeding

Death

1

Gastric ulcer; renal failure

Recent orthopedic surgery; obesity; vena cava filter

Confirmed

Yes x 2

No

No

No

No

2

Antiplatelet treatment

-

Confirmed

No

No

No

No

No

3

Cardiac surgery; renal failure

AF

Confirmed

Yes

No

Yes, hematuria

No

Yes, cardiogenic shock

4

Antiplatelet treatment

Obesity; DVT; PE; lupus anticoagulant

Confirmed

Yes x 2

Yes x 4

No

No

No

3 DVT extension

1 new

5

Antiplatelet treatment; renal failure

Sepsis; AF

Confirmed

No

No

No

No

No

6

Acute renal failure; moderate hepatic cystosis

DVT; sepsis

Confirmed

Yes

No

No

No

No

7

Renal failure; cardiac insufficiency; liver insufficiency

DVT; PE

Not confirmed

Yes

No

No

No

Yes, congestive heart failure

8b

Acute renal failure; hepatic insufficiency; gastric ulcer; abdominal surgery; overdose

Cancer; sepsis; PE

Not confirmed

Yes x 2

Yes x 2

No

Yes

Yes, MOF but after end of FU period

2 new

9

Digestive angiodysplasia; renal failure

AF; cardiac insufficiency

Confirmed

Yes

Yes, new-limb ischemia

No

No

No

10

-

Sepsis; DVT; PE

Confirmed

Yes x 2

No

No

No

Yes, refractory hypoxemia due to ARDS

11

Abdominal and cardiac surgery

Cancer; cardiac surgery; sepsis

Confirmed

Yes x 2

No

No

No

No

12

Hepatic impairment and cardiac surgery

Cardiac surgery

Confirmed

No

No

No

No

No

13

Acute kidney failure; intra-alveolar hemorrhage

Obesity; cardiac insufficiency; sepsis

Confirmed

Yes

No

No

No

No

14c

Renal failure; hepatic insufficiency; cardiac surgery

Cardiac insufficiency; intra-aortic balloon pump; cardiac surgery

Confirmed

Yes x 2

No

Yes, rectorrhagia

Yes, hematemesis

Yes, MOF and refractory shock

15

-

Arterial thrombosis; sepsis

Confirmed

Yes

Yes, new right internal jugular vein thrombosis, catheter-related

No

No

No

16

Renal failure; acute hepatic insufficiency

Cardiac insufficiency; AF; varicose vein

Not confirmed

No

No

No

No

No

17

Acute renal failure; vascular surgery

Obesity; AF; sepsis; arterial thrombosis

Confirmed

Yes

Yes

Yes, due to puncture of dialysis catheter

No

Yes, sepsis with MOF

18

Renal insufficiency; fissuring aneurysm

Suspected cancer; vascular surgery; arterial thrombosis; PE

Not confirmed

Yes x 2

No

No

No

Yes, degradation of general condition complicated by per-renal azotemia

19d

Renal insufficiency; aortic dissection surgery; antiplatelet therapy

Obesity; cardiac insufficiency; sepsis

Confirmed

No

No

No

No

No

20

Renal failure and cardiac surgery

Obesity; cardiac surgery; cardiac insufficiency

Confirmed

No

No

No

No

No

Total

   

14 yes

5 yes

3 x major

2 x non major

7 yes (1 died after end of FU period); all deaths due to underlying diseases

  1. aBaseline thrombosis: all confirmed thromboses that were ongoing at the start of argatroban infusion. bPatient 8 had an overdose/medication error. The patient was infused 10.5 μg/kg/min for approximately 1 hour as the study nurse mixed up two pumps. No major bleeding occurred. The death of this patient was not included in this study as it occurred outside the study period. cPatient 14 had Child Pugh class C at the time of inclusion.
  2. dPatient 19 was treated with danaparoid for 16 days before the start of the argatroban infusion. This patient was no longer in the acute HIT phase
  3. AF atrial fibrillation, ARDS acute respiratory distress syndrome, DVT deep vein thrombosis, FU follow up; PE pulmonary embolism, MOF multiple organ failure